⚡️⚡️⚡️
With energy prices rising, switch to a cheaper plan
💡
Compare Prices Now
⚡️⚡️⚡️

How to buy Zoetis (ZTS) shares in Australia

Learn how to easily invest in Zoetis shares.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Zoetis Inc (ZTS) is a leading drug manufacturers-specialty & generic business with stocks listed in the US. It opened the day at US$208.03 after a previous close of US$208.62. During the day the price has varied from a low of USD206.84 to a high of USD209.075. The latest price was USD208.51 (25 minute delay). Zoetis is listed on the NYSE. All prices are listed in US Dollars.

How to buy shares in Zoetis

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Zoetis. Find the share by name or ticker symbol: ZTS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Zoetis reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$208.62, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Zoetis, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Zoetis. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Zoetis stock price (NYSE:ZTS)

Use our graph to track the performance of ZTS stocks over time.

Zoetis shares at a glance

Information last updated 2021-10-22.
OpenUS$208.03
HighUS$209.075
LowUS$206.84
CloseUS$208.51
Previous closeUS$208.62
Change US$-0.11
Change % -0.0527%
Volume 979,765
Information last updated 2022-06-25.
52-week rangeUS$154.18 - US$248.4353
50-day moving average US$169.9052
200-day moving average US$197.6252
Target priceUS$236.9
PE ratio 40.0574
Dividend yield US$1.075 (0.8%)
Earnings per share (TTM) US$4.359

Compare trading apps to buy Zoetis shares

1 - 7 of 7
Name Product Standard brokerage for US shares Currency conversion fee Markets
eToro (global stocks)
US$0
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
US$0
0.70%
ASX shares, US shares, UK shares, ETFs, and more
Exclusive: Finder customers who apply for a share trading account in June will be able to trade Aussie shares from $2.50 commission until the end of August. T&Cs apply.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Tiger Brokers
Exclusive
Tiger Brokers
US$1.99
N/A
ASX shares, Global shares, Options trading, US shares, ETFs
Exclusive to Finder: Sign up to Tiger through Finder and on completion of your first deposit of any amount or transfer of shares receive 4 extra free grab shares. T&Cs apply.
Get started with $0 brokerage on ASX and US stocks for the first 3 months upon completion of your first qualifying deposit. Also receive a free Apple share if you deposit $3,000 or more.
SelfWealth (Basic account)
US$9.5
0.60%
ASX shares, US shares
Trade ASX and US shares for a flat fee of $9.50, regardless of the trade size.
New customers receive free access to Community Insights with SelfWealth Premium for the first 90 days. Follow other investors and benchmark your portfolio performance.
Bendigo Invest Direct
$0
0.60%
ASX shares, Global shares, Options trading, mFunds, ETFs, Warrants
Gain access to 12 markets from one account with Bendigo.
Invest in Australian shares and access major international markets through a trusted local brand. Plus, fine tune your investment knowledge with Bendigo’s advanced research and analysis tools.
Saxo Capital Markets (Classic account)
US$4
1%
ASX shares, Global shares, ETFs
Access 22,000+ stocks on 50+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
Superhero share trading
US$0
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares, ETFs
Sign up & fund your account with A$100 or more and receive US$10 of Tesla stocks on Superhero. T&Cs apply.
Enjoy $0 brokerage on US stocks and buying ETFs as well as a flat $5 fee to trade Australian shares.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Zoetis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Zoetis share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Zoetis price performance over time

Historical closes compared with the last close of $208.51

1 week (2022-06-21) 28.70%
1 month (2022-05-25) 27.90%
3 months (2022-03-28) 10.11%
1 year (2021-06-28) 11.45%
2 years (2020-06-26) 57.18%
3 years (2019-06-28) 83.73%
5 years (2017-06-28) 231.23%

Is Zoetis under- or over-valued?

Valuing Zoetis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zoetis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Zoetis's P/E ratio

Zoetis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, Zoetis shares trade at around 40x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Zoetis's PEG ratio

Zoetis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.9815. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zoetis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Zoetis's EBITDA

Zoetis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$3.2 billion (£2.7 billion).

The EBITDA is a measure of a Zoetis's overall financial performance and is widely used to measure a its profitability.

Zoetis financials

Revenue TTM US$7.9 billion
Operating margin TTM 36.05%
Gross profit TTM US$5.5 billion
Return on assets TTM 12.86%
Return on equity TTM 47.31%
Profit margin 26.27%
Book value 9.885
Market capitalisation US$82.2 billion

TTM: trailing 12 months

Zoetis's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Zoetis.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Zoetis's total ESG risk score

Total ESG risk: 28.6

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Zoetis's overall score of 28.6 (as at 01/01/2019) is nothing to write home about – landing it in it in the 49th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Zoetis is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Zoetis's environmental score

Environmental score: 2.72/100

Zoetis's environmental score of 2.72 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Zoetis's social score

Social score: 13/100

Zoetis's social score of 13 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Zoetis's governance score

Governance score: 8.87/100

Zoetis's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Zoetis is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Zoetis's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Zoetis scored a 1 out of 5 for controversy – the highest score possible, reflecting that Zoetis has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Zoetis Inc was last rated for ESG on: 2019-01-01.

Total ESG score 28.6
Total ESG percentile 49.38
Environmental score 2.72
Environmental score percentile 1
Social score 13
Social score percentile 1
Governance score 8.87
Governance score percentile 1
Level of controversy 1

Zoetis share dividends

26%

Dividend payout ratio: 25.74% of net profits

Recently Zoetis has paid out, on average, around 25.74% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.8% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Zoetis shareholders could enjoy a 0.8% return on their shares, in the form of dividend payments. In Zoetis's case, that would currently equate to about $1.075 per share.

While Zoetis's payout ratio might seem fairly standard, it's worth remembering that Zoetis may be investing much of the rest of its net profits in future growth.

Zoetis's most recent dividend payout was on 1 September 2022. The latest dividend was paid out to all shareholders who bought their shares by 20 July 2022 (the "ex-dividend date").

Zoetis share price volatility

Over the last 12 months, Zoetis's shares have ranged in value from as little as US$154.18 up to US$248.4353. A popular way to gauge a stock's volatility is its "beta".

ZTS.US volatility(beta: 0.77)Avg. volatility(beta: 1.00)LowHigh

Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zoetis's is 0.7677. This would suggest that Zoetis's shares are less volatile than average (for this exchange).

Zoetis overview

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Zoetis in the news

There are no recent company news

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site